Recurrent Vulvovaginal Candidiasis Clinical Trial
Official title:
A Randomized, Double-Blind, Double-Dummy, Parallel Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis (RVVC)
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04029116 -
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
|
Phase 3 | |
| Active, not recruiting |
NCT04734405 -
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
|
Phase 2/Phase 3 | |
| Completed |
NCT01067131 -
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
|
Phase 1 | |
| Completed |
NCT03840616 -
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
|
Phase 3 | |
| Recruiting |
NCT04699240 -
Study of Lactobacillus in Adjuvant Treatment of RVVC
|
Phase 4 | |
| Not yet recruiting |
NCT04639544 -
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis
|
N/A | |
| Completed |
NCT02267382 -
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 2 | |
| Recruiting |
NCT06190509 -
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
|
Phase 1/Phase 2 | |
| Completed |
NCT03561701 -
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 3 | |
| Completed |
NCT03562156 -
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 3 | |
| Enrolling by invitation |
NCT05795491 -
Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis
|
N/A | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 |